Monashee Investment Management LLC Takes Position in Denali Therapeutics Inc. $DNLI

Monashee Investment Management LLC purchased a new stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 91,620 shares of the company’s stock, valued at approximately $1,513,000. Monashee Investment Management LLC owned about 0.06% of Denali Therapeutics as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Headlands Technologies LLC purchased a new stake in shares of Denali Therapeutics during the 2nd quarter valued at about $26,000. Johnson Financial Group Inc. purchased a new stake in shares of Denali Therapeutics during the 3rd quarter valued at about $29,000. State of Wyoming purchased a new stake in shares of Denali Therapeutics during the 2nd quarter valued at about $29,000. Quarry LP purchased a new stake in shares of Denali Therapeutics during the 3rd quarter valued at about $64,000. Finally, Eurizon Capital SGR S.p.A. purchased a new stake in shares of Denali Therapeutics during the 4th quarter valued at about $83,000. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Robert W. Baird upped their price target on shares of Denali Therapeutics from $32.00 to $34.00 and gave the company an “outperform” rating in a research report on Tuesday, April 7th. The Goldman Sachs Group upped their price target on shares of Denali Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Morgan Stanley reduced their price target on shares of Denali Therapeutics from $40.00 to $35.00 and set an “overweight” rating for the company in a research report on Friday, May 22nd. Wall Street Zen raised shares of Denali Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Wedbush reduced their target price on shares of Denali Therapeutics from $25.00 to $23.00 and set an “outperform” rating for the company in a report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.25.

Denali Therapeutics Trading Up 2.0%

Denali Therapeutics stock opened at $21.02 on Friday. The firm has a 50 day moving average of $19.76 and a 200 day moving average of $19.43. The firm has a market capitalization of $3.34 billion, a price-to-earnings ratio of -7.30 and a beta of 1.03. Denali Therapeutics Inc. has a 12-month low of $12.58 and a 12-month high of $23.77. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Thursday, May 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.04. During the same quarter in the previous year, the business earned ($0.78) earnings per share. As a group, research analysts predict that Denali Therapeutics Inc. will post -2.77 earnings per share for the current year.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical?stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine?rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti?TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.